Scienmag

DECEMBER 10, 2020

Using optical biosensor technology, the test provides quantitative measurements of antibodies in blood plasma in less than 20 minutes Credit: Carolyn Lagattuta Researchers at UC Santa Cruz have developed a novel serological assay for the detection of antibodies to SARS-CoV-2, the coronavirus that causes COVID-19.

Antibody 98

Antibody Engineer Development Research 98

Scienmag

JANUARY 4, 2021

In advance of public vaccination, a quick and accurate COVID-19 antibody test will help determine the presence of neutralizing antibodies, the molecules that aid in protection against the virus. Credit: UAB BIRMINGHAM, Ala.

Vaccine 98

Vaccine Vaccination Antibody Development 98

Delveinsight

AUGUST 27, 2020

The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults. Freenome secures USD 270 Million to boost its colorectal cancer blood test. White fat, in contrast, can build up and cause obesity.

Vaccine 53

Vaccine Vaccination Research Trials 53

Scienmag

SEPTEMBER 9, 2020

Computer design of synthetic proteins is creating potent, stable antivirals that block infection at least as well as monoclonal antibodies Credit: Ian Haydon/UW Medicine Institute for Protein Design Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.

Protein 40

Protein Antibody Medicine Allergies 40

The Pharma Data

JUNE 25, 2021

The CDC has defined Variant of Interest (VoI) as a variant with genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, or predicted increase in transmissibility or disease severity. BARDA is providing up to $1.75 About NVX-CoV2373.

Vaccine 40

Vaccine Vaccination Trials Immune Response 40

pharmaphorum

FEBRUARY 9, 2021

An international trial led by US experts is to begin testing AstraZeneca’s long-acting antibody combination therapy to treat COVID-19. It is sponsored by the US-government funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Antibody 52

Antibody Trials Allergies Engineer 52

XTalks

NOVEMBER 30, 2023

Preclinical data demonstrated that HB-500 was well-tolerated, eliciting robust, high-quality and enduring immune responses, including antigen-specific T cells and antibodies, in non-human primates. In November 2023, Hookipa Pharma Inc., Notably, it significantly reduced viral load and clinical illness compared to a placebo.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111